Alejandro González-Motta

MD, Radiation Oncology, Colombia 🇨🇴. 🏨 Centro de Tratamiento e investigación sobre Cáncer -CTIC. Opita. Opiniones personales.

[Dr. Nina Niu Sanford @NiuSanford]

Neo-CRAG: Ph3 RCT (n=620, gastric/GEJ) - adding neoadj chemoRT to peri-op XELOX improved OS (68 v 38 mo).

Limitation=non-FLOT, BUT still relevant IMO b/c:

1) DFS/OS benefit substantial.
2) Improvements in pCR, downstg, LRR supports plausible RT effect on OS. #ASCO26 @OncoAlert

[Bobby Koneru, MD @KoneruMd]

🚨The first American guidelines for low-dose radiotherapy in osteoarthritis were just published.

That’s not a small thing.

For decades, European centers have been treating OA with low-dose RT. American patients largely couldn’t access it. No formal guidance. No insurer framework. No roadmap for referring providers.

That changes today.

The American Radium Society Appropriate Use Criteria, published in the American Journal of Clinical Oncology, define exactly when and how to use LDRT for OA. Radiation oncologists, rheumatologists, physiatrists, and orthopedic surgeons built this together.

For insurers, this is the clinical framework they’ve been waiting for.

Honored to be a co-author alongside the global experts who made this possible.

[Dr Rupam Manna MD @DrRupamOncology]

🔥 How to Differentiate N1 vs N2 Disease in NSCLC
(IASLC Lymph Node Map – TNM 9th Edition)
The #1 decision that decides resectability & treatment in Stage III lung cancer!
✅ N1 (stations 10–14) = ipsilateral hilar & intrapulmonary nodes → Usually straightforward surgery
✅ N2 (stations 2–9) = ipsilateral mediastinal + subcarinal nodes → Stage III, needs MDT
✅ Crystal-clear anatomical boundaries (Azygos vein on right, left main PA on left)
✅ Brand new 9th edition: N2a (single-station) vs N2b (multistation)
✅ Practical tools: PET-CT → EBUS-TBNA → Mediastinoscopy
Perfect quick reference for DM/DNB Oncology residents, thoracic surgeons, medical oncologists & pulmonologists!
✅ 100% accurate as per IASLC TNM 9th Edition & latest NCCN/ESMO guidelines
Full infographic below ���
#NSCLC #LungCancer #N1vsN2 #LungCancerStaging #IASLC #StageIII #Oncology #MedTwitter #MedEd #CancerConceptsExplained
Follow @DrRupamOncology for more simplified oncology visuals!

[Yakup Ergün @dr_yakupergun]

#ASCO26
DESTINY-Breast05 ILD analysis

ILD was more frequent with T-DXd.

Interesting signal:
ILD was more common in Japan.
Genetic susceptibility, imaging/diagnostic threshold, reporting practice, and RT techniques may all contribute.

RT timing does not seem to make a major difference:
T-DXd ILD
Sequential RT: 10.7%
Concurrent RT: 9.6%

@SuyogCancer , this may be the answer to the question you raised in the wp group🙂
Of course, the radiotherapy device/technique used probably matters as well.

[International Consortium on Meningiomas (ICOM) @ICOMeningioma]

The integration of #DNAMethylation and Copy Number Variation-profiles into the IntS unified risk score offer an enhanced prognostic differentiation of #Meningioma patients - this was the finding from a recent study published in @JNeurooncol.

Read here: https://t.co/fSOrJpLgLB

[Mario Balsa @MarioBalsaMD]

🫁 Metastatic trajectories in NSCLC: redefining local + systemic therapy through disease evolution! @JCO_ASCO
https://t.co/XcpEhaGHML

▪️ Genomics + ctDNA + radiomics + functional imaging
▪️ Defines progression by pace, pattern, organotropism & resistance mechanisms
▪️ Adaptive strategies: escalate, switch, consolidate or locally ablate
▪️ Could reshape biomarker-driven platform trials in mNSCLC

Not all metastases follow the same road…some take very different “trajectories” 🚦

@OncoAlert @OncoReporte
@myESMO @_SEOM @LungCancerRx @Lung_Cancers @gecp_org

[Alexander Sherry @AlexSherryMD]

1/ Tremendous thanks to the patients, coauthors and all who made the EXTEND trial possible. The primary aggregated analysis is now available online @JCO_ASCO with ctDNA correlatives presented synchronously at @ESTRO_RT #ESTRO26

[Sushil @Sushilberiwal]

@piet_ost summarizing role of RT in stage IV disease

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Joint ESTRO-ASTRO - Prostate cancer horizons:
Imaging, treatment & global insights from ESTRO, ASTRO and APCCC

✨Primary treatments: Choosing the best strategy and fractionation
@ESTRO_RT @ASTRO_org #ESTRO26
@OncoAlert #OncoAlertAF @alison_tree

[ASTRO @ASTRO_org]

New in #practicalRO: Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases: A Case-Based Radiosurgery Society Review. #radonc https://t.co/hv2T4Nbvpx

[Shankar Siva @_ShankarSiva]

📣 #ESTRO26 - @UmbertoRicardo e2irradiate @EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets.
➡️ local failure 5% at 1 year and 11% at 3 years
➡️ Colorectal cancer has higher risk of progression
➡️ minimum PTV dose correlated with outcome

We should aim to deliver high quality SABR to optimise control! #radonc

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Metastases-directed treatment in Patients with Oligometastatic Breast Cancer: Results from the OLIGOMA-trial (ARO-2021-09, NCT04495309) @DavidKrugMD 👏🏻 #ESTRO26 @ESTRO_RT @OncoAlert #OncoAlertAF

[Shankar Siva @_ShankarSiva]

20-year outcomes of @EORTC internal mammary #radiotherapy trial.
➡️internal mammary improved control
➡�� survival counterbalanced by late adverse events #radiotherapy
#bcsm
Great to see the long term data at #ESTRO26, and discussing Charlotte Cole suggests with modern RT, long term cardiac risk is ⬇️

[Piet Ost @piet_ost]

DART results: Darolutamide added to SBRT for PSMA PET recurrent mHSPC temporary improves PSA responses and MFS, with a temporary increase in hormonal G1-2 adverse events. Thank you to all the patients and Belgian collaborators. @ESTRO2026 @Bayer

[Piet Ost @piet_ost]

5-year update of FASTTRACK: SABR for kidney cancer by @_ShankarSiva. Organ-sparing at its best A single arm study that changed the guidelines! Stellar effort for the our field and our patients.#ESTRO26 https://t.co/ehJHz7AKU2

[radoncreview_org @radoncreview]

Our “Best of” #ESTRO26 outline is now live! 🚀

What key studies are we missing?

Drop any important trials, abstracts, or presentations we should add 👇

https://t.co/MyeQVhxxSk

#RadOnc #ESTRO26 #ESTRO2026

[Alejandro González-Motta @Alejogom]

@ArenaAlfaUS Profe desafortunadamente siempre están los que quieren el camino fácil sin respeto por el trabajo y esfuerzo de otro. Yo soy nuevo por acá, pero estoy muy agradecido por la educación y el contenido. Siempre gracias.

[Alejandro González-Motta @Alejogom]

@RadioOncologia @pablomunozsch @Solar_Latam @ASTRO_org @ESTRO_RT @ASCO Thanks! 🤓😃.

[Andre G, MD, Rad Onc ⚽️ 🇮🇹 🇨🇦 @RadioOncologia]

Congrats! @pablomunozsch @Alejogom

[Enrique Grande @drenriquegrande]

⚡️ Phase II data suggest that adding pembrolizumab to trimodal therapy may be a feasible bladder-preserving strategy for selected patients with MIBC.

At 2 years:

• Bladder-intact DFS: 60%
• Metastasis-free survival: 81%
• Overall survival: 83%

Further phase III validation will be key.

#BladderCancer #Immunotherapy @ASCOPost @EUplatinum

https://t.co/Gyuo12eGR1